Doximity, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DOCS research report →
Range $23 – $41
Price Chart
About the company
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers.
- CEO
- Jeffrey A. Tangney
- IPO
- 2021
- Employees
- 880
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on DOCS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.12B
- P/E
- 38.31
- Fwd P/E
- 21.38
- PEG
- -0.87
- P/S
- 7.74
- P/B
- 5.53
- EV/EBITDA
- 22.29
- Div Yield
- 0.00%
- Gross Margin
- 86.83%
- Op Margin
- 26.34%
- Net Margin
- 21.12%
- ROE
- 14.81%
- ROIC
- 12.60%
Latest fiscal year · YoY change
- Revenue
- $644.86M+13.1%
- Gross Profit
- $574.54M+11.7%
- Op Income
- $214.92M
- Net Income
- $196.05M-12.2%
- EPS
- $1.05-11.8%
- OCF Growth
- +19.5%
- FCF Growth
- +19.0%
- 52W High
- $51.85
- 52W Low
- $17.15
- 50D MA
- $30.22
- 200D MA
- $25.09
- Beta
- 1.29
- RSI (14)
- 35
- Avg Volume
- 2.74M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Doximity delivered a modest revenue beat with strong AI-driven engagement and margins, while raising full-year guidance on improving AI search visibility and cost efficiency.· November 5, 2026
- Q2 revenue was $175 million, up 4% year over year and above the high end of guidance; adjusted EBITDA margin was 51% ($89 million), 9 points above the high end of guidance.
- AI usage continued to accelerate: quarterly active workflow prescribers grew 34% year over year to record highs, and management said roughly half of U.S. prescribers used the workflow tools last quarter.
- AI search is gaining traction with pharma: 16 of the Top 20 pharma companies have purchased, 3 more are in contracting, and management said AI search is now an 8-figure bookings product.
- Health system adoption also expanded, with AI clients rising to over 190 from 165 last quarter, including 10 of the nation’s Top 20 hospitals.
- Management raised FY27 revenue guidance to $678 million to $683 million and adjusted EBITDA guidance to $317 million to $325 million, while expecting AI investment to continue through the year.
Q2 revenue was $175 million, up 4% year over year and 2 percentage points above the high end of guidance. Adjusted EBITDA was $89 million with a 51% margin, or 9 percentage points above the high end of guidance. Non-GAAP gross margin was 88% versus 92% last quarter. GAAP diluted EPS was $0.18 and non-GAAP diluted EPS was $0.36. Free cash flow was $91 million, cash/cash equivalents/marketable securities ended at $713 million, and the company remained debt free. For Q3, Doximity guided to revenue of $190 million to $196 million and adjusted EBITDA of $102.5 million to $103.5 million. For FY27, revenue guidance was raised to $678 million to $683 million and adjusted EBITDA guidance to $317 million to $325 million.
Jeffrey A. Tangney framed the quarter around three themes: financial performance, AI accuracy, and engagement. He emphasized that Doximity is leading on clinical AI safety with DoseCheck and the addition of UpToDate, calling accuracy the top concern doctors have about AI. He also highlighted growing workflow adoption, deeper health system integration, and a broader push into pharma search, saying the company is expanding from a media business into a media-and-search platform.
Matthew Sonefeldt said the quarter validated Doximity’s decision to expand AI investment in FY27 because usage growth is driving broader workflow adoption. He pointed to improving AI cost efficiency, noting cost of revenue grew at less than half the rate of prompt volume in Q2, and that adjusted EBITDA outperformance came from both revenue upside and better-than-expected AI efficiency. He also cited $713 million in cash, no debt, $91 million of free cash flow, $54 million of share repurchases, and 188 million fully diluted shares, while saying SBC was $41 million, or 23% of revenue.
Analysts focused on AI search traction, monetization, and whether the product is incremental or cannibalizing existing spend. Management said AI search is mostly incremental, tied largely to a separate pharma search budget, and that the primary monetization is on the pharma side as an advertising product, while health system monetization is a nominal fee as part of the broader workflow suite. Questions also centered on health system governance and EHR integration; management said patient context can roughly double usage, but simply being inside an EHR does not guarantee adoption without training, and they view tighter AI governance as a tailwind because Doximity’s product is designed for security and accountability.
The bull case from this call is that Doximity is seeing real acceleration in clinician workflow usage while preserving strong margins. Management believes AI search opens a much larger pharma budget pool, with 16 of the Top 20 already buying and more demand building. The company also has growing health system distribution, strong cash generation, and early evidence that AI investments are improving engagement and could support future revenue leverage.
The main risks discussed were that AI search revenue will ramp gradually because medical-legal review can take many months, especially for first-time customers. Management also said Q4 visibility remains lower until the upfront season finishes, and the year implies only modest growth acceleration, not a dramatic reacceleration. On top of that, gross margin fell from last quarter as AI costs scaled, and management acknowledged that some of the growth metrics like NRR and large-customer expansion are currently at trough-like levels.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.0%
- Shares Outstanding
- 178.24M
- Float Shares
- 172.83M
of shares held by institutions
379 13F filers
Buy/sell ratio 0.48. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for DOCS, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 14.35M | ▲ 47.72K |
| Vanguard Group Inc | 13.29M | ▲ 518.92K |
| D. E. Shaw & Co., Inc. | 5.92M | ▲ 3.02M |
| Vanguard Capital Management LLC | 5.53M | ▼ 442.54K |
| Vanguard Portfolio Management LLC | 5.34M | ▼ 1.05M |
| Two Sigma Investments, LP | 4.65M | ▲ 3.28M |
| State Street Corp | 4.14M | ▼ 75.14K |
| Goldman Sachs Group Inc | 4.09M | ▲ 2.32M |
| Geode Capital Management, LLC | 3.58M | ▼ 265.17K |
| Bnp Paribas Financial Markets | 3.15M | ▲ 452.67K |
| Wellington Management Group Llp | 3.14M | ▲ 621.46K |
| Renaissance Technologies LLC | 2.68M | ▼ 169.20K |
Held by 542 ETFs
Biggest fund positions in DOCS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Tangney Jeffrey | other | 8,506 |
| Nov 16, 26 | Sitaram Siddharth | other | 8,000 |
| Nov 16, 26 | Sitaram Siddharth | sell | 2,523 |
| Nov 15, 26 | Sitaram Siddharth | other | 2,824 |
| Nov 16, 26 | Sitaram Siddharth | other | 3,000 |
| Nov 16, 26 | Sitaram Siddharth | other | 5,000 |
| Nov 16, 26 | Sitaram Siddharth | other | 8,000 |
| Nov 16, 26 | Sitaram Siddharth | other | 8,000 |
| Nov 15, 26 | ZATZ STEVEN L | other | 15,083 |
| Nov 15, 26 | Sonefeldt Matthew | other | 21,188 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DOCS coverage
Recent articles, reports, and earnings notes.

What to Watch as Pearl’s SPAC Merger Moves Toward Close
Pearl appears to be the dental AI company, and the deal context points to a possible public listing through K&F Growth Acquisition Corp. II (Nasdaq: KFII). But the SEC materials surfaced here do not verify a signed merger agreement, so investors should watch for the actual S-4/proxy, valuation, and financing terms before treating this as a live de-SPAC. The setup could be attractive if the company is real and the terms are clean, but the missing deal documents leave the core economics unconfirmed.

Tempus AI's 24% stealth rally is a bull signal, not a mystery
TEM’s 24.1% headline-free surge looks like investors repricing a real profitability inflection, not chasing an empty AI story. Q2 revenue growth, a guidance raise and a path to positive cash flow give the rally a fundamental anchor despite expensive valuation.

TEM's 13% stealth rally is ignoring the Personalis bill
TEM's 13% surge is running ahead of an unprofitable business and a $1.5 billion Personalis deal that adds scale before it adds clean earnings. Strong revenue growth is real, but dilution, cash needs, and insider selling make this rally one to fade rather than chase.
Want a deeper read on DOCS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Here's Why You Should Retain Doximity Stock in Your Portfolio for Now
zacks.com · Nov 20
Doximity, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOCS
prnewswire.com · Nov 16
DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems
zacks.com · Nov 16
Bronstein, Gewirtz & Grossman LLC Urges Doximity, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com · Nov 16
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law
businesswire.com · Nov 16
DEADLINE ALERT for Doximity, Inc. (DOCS), Better Home & Finance Holding Company (BETR), Honeywell Aerospace, Inc. (HONA) and Tigo Energy, Inc. (TYGO): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
globenewswire.com · Nov 16
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law
gurufocus.com · Nov 16
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law
prnewswire.com · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.